Evidence map›Paper›PMID 41568097›Full record

ArticleComputational and structural biotechnology journal2026

Empirical optimization of dual-sgRNA design for in vivo CRISPR/Cas9-mediated exon deletion in mice.

Sung-Yeon Lee, Seongwon Ma, Sangjun Davie Jeon, Hyoju Kim, Beomjoon Jo, Seung-Hoon Han, Eunsoo Jang, Jimin Lee, Yong-Kyu Lee, Dasom Lee

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sung-Yeon LeeGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Seongwon MaGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Sangjun Davie JeonGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Hyoju KimGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Beomjoon JoGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Seung-Hoon HanGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Eunsoo JangGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Jimin LeeGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Yong-Kyu LeeGEM Division, Macrogen Inc., Seoul, Republic of Korea.
Dasom LeeGEM Division, Macrogen Inc., Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas9 has transformed gene editing, enabling precise genetic modifications across species. However, existing sgRNA design prediction models based on in vitro data are difficult to generalize to in vivo contexts. In particular, approaches based on single-sgRNA design require additional filtering of in-frame mutations, which is inefficient in terms of both time and cost. In this study, we developed the first mammalian in vivo-trained prediction model to evaluate the efficiency of a dual-sgRNA-based exon deletion strategy. Using 230 editing outcomes of postnatal viable individuals, eight prediction models were constructed and evaluated based on generalized linear models and Random Forests. The final selected model, a Combined GLM, integrated the DeepSpCas9 score with k-mer sequence features, achieving an AUC of 0.759 (95 % Confidence Interval: 0.697-0.821). Motif analysis revealed that CC sequences were associated with high efficiency and TT sequences were associated with low editing efficiency. This study demonstrates that integrating sequence-based features with existing design scores can improve sgRNA efficiency prediction in vivo. The proposed framework can be applied to the development of next-generation sgRNA design tools, with implications for gene therapy, effective animal model generation, and precision genome engineering.

Indexed as

CRISPR/Cas9Dual-sgRNAExon deletionIn vivo genome editingMouse model

Identifiers

PMID41568097
PMCPMC12818265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.